An Introduction to Integrative Oncology for Healthcare Professionals
Module 9 Assessment

1. Indicate which of the following is an example of drug re-purposing: I. The use of sunitinib (approved in kidney cancer) in a patient with breast cancer who has chromosome 4p amplification II. The use of aspirin in a patient with PIK3CA-mutated colorectal cancer III. The use of metformin in combination with anti-androgen therapy in a patient with prostate cancer.
2. What proportion of patients have problems that are easily addressed by evidence-based medicine:
3. Treatments without single agent anti-tumor activity of at least 10% have no clinical value.
4. The “hallmarks of cancer” defined by Hanahan and Weinberg in 2000 and 2011 include which of the following? Tick all that are true:
5. Does the PI3K-AKT signaling pathway do”
6. Potential approaches to AKT blockade include:
7. Treating unusual or rare mutations in is of no value:
8. Genomic instability results from:
9. Chromosome 4q12 amplification can be approached with sunitinib. Which 3 oncogenes are present at 4q12?
10. Obstacles to re-purposing include: (Tick all that apply)

Thanks for submitting!